bioRxiv Science⌕ Search

Biology subjects

McIntosh, S.

Publications and source records attributed to McIntosh, S..

2 recordsLinked to original sources

From Policy to Practice: Tracking an Open Science Funding Initiative

This is a critical moment in the open science landscape. Over the past few years there has been growing momentum to improve open research policies and require grantees to share all research outputs, from datasets to code to protocols, in FAIR (findable, accessible, interoperable and reusable [FAIR]) repositories with persistent identifiers attached. The Aligning Science Across Parkinsons (ASAP) initiative has made substantial investments in improving open science compliance monitoring for its grantees, requiring grantees to update their manuscripts if not all research outputs have been linked in the initial manuscript version. Here, we evaluate ASAPs effectiveness in improving research output sharing for all articles processed through the ASAP compliance workflow between March 1, 2022, and October 1, 2022. Our ultimate goal in sharing our findings is to assist other funders and institutions as they consider open science implementation. By normalizing the open science and compliance process across funding bodies, we hope to simplify and streamline researcher, institutional, and funder workflows, allowing researchers to focus on science by easily leveraging resources and building upon the work of others.

scientific communication and education↗

Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Addiction States

Substance use and related mental health epidemics are causing increasing suffering and death in diverse communities.1,2 Despite extensive efforts focused on developing pharmacotherapies for treating substance use disorders, there is an urgent need for radically different therapeutic approaches.3,4 Ibogaine provides an important drug prototype in this direction, as a psychoactive iboga alkaloid suggested to have the ability to interrupt opioid use in drug-dependent humans.5 However, ibogaine and its major metabolite noribogaine present considerable safety risk associated with cardiac arrhythmias.6 We introduce a new class of iboga alkaloids - "oxa-iboga" - defined as benzofuran-containing iboga analogs and created via structural editing of the iboga skeleton. The oxa-iboga compounds act as potent kappa opioid receptor agonists in vitro and in vivo, but exhibit atypical behavioral features compared to standard kappa psychedelics. We show that oxa-noribogaine has greater therapeutic efficacy in rat models of opioid use, and no cardiac pro-arrhythmic potential, in contrast to noribogaine. Oxa-noribogaine induces long-lasting suppression of morphine and fentanyl intake after a single dose, persistent reduction of morphine intake and reinforcing efficacy after a short treatment regimen, and suppression of morphine and fentanyl drug seeking in relapse models. Oxa-noribogaine also induces a lasting elevation of neurotrophin proteins in the ventral tegmental area and medial prefrontal cortex, consistent with targeted neuroplasticity induction and alteration of addiction-like states. As such, oxa-iboga compounds represent candidates for a novel type of pharmacotherapy for treatment of opioid use disorder.

pharmacology and toxicology↗